Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
C4 Therapeutics initiated with a Buy at Brookline » 08:45
06/24/21
06/24
08:45
06/24/21
08:45
CCCC

C4 Therapeutics

$37.82 /

-0.53 (-1.38%)

Brookline analyst Leah…

Brookline analyst Leah Rush Cann initiated coverage of C4 Therapeutics with a Buy rating and $54 price target. She estimates clinical-stage biopharmaceutical company developing novel therapeutic candidates to target disease-causing proteins for the treatment of cancer could launch its first drugs, CFT7455 and CFT8634, by 2026. She also estimates C4 has sufficient cash to fund development of its programs through 2023 and will need approximately $600M of additional cash in 2024-2026 to fund the development of CFT7544, CFT8634, CFT8919, and its BRAF and RET programs.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$37.82 /

-0.53 (-1.38%)

CCCC C4 Therapeutics
$37.82 /

-0.53 (-1.38%)

06/22/21 BMO Capital
C4 Therapeutics price target lowered to $53 from $55 at BMO Capital
06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
  • 17
    Jun
  • 02
    Oct
CCCC C4 Therapeutics
$37.82 /

-0.53 (-1.38%)

CCCC C4 Therapeutics
$37.82 /

-0.53 (-1.38%)

Recommendations
C4 Therapeutics price target lowered to $53 from $55 at BMO Capital » 09:17
06/22/21
06/22
09:17
06/22/21
09:17
CCCC

C4 Therapeutics

$38.52 /

+0.52 (+1.37%)

BMO Capital analyst…

BMO Capital analyst Matthew Luchini lowered the firm's price target on C4 Therapeutics to $53 from $55 but keeps an Outperform rating on the shares. The analyst cites the company's insights into preclinical activity of CFT7455 in Non-Hodgkins Lymphomas at the ICML this past weekend, noting that while it is still early, the data "support a potential best-in-class degrader given promising activity across multiple NHL subtypes". Luchini adds however that his reduced price target reflects the company's recent financing with increased dilution.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$38.52 /

+0.52 (+1.37%)

CCCC C4 Therapeutics
$38.52 /

+0.52 (+1.37%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 17
    Jun
  • 02
    Oct
CCCC C4 Therapeutics
$38.52 /

+0.52 (+1.37%)

CCCC C4 Therapeutics
$38.52 /

+0.52 (+1.37%)

Hot Stocks
C4 Therapeutics presents preclinical data on CFT7455 » 08:22
06/21/21
06/21
08:22
06/21/21
08:22
CCCC

C4 Therapeutics

$38.00 /

+0.8 (+2.15%)

C4 Therapeutics presented…

C4 Therapeutics presented pre-clinical data for CFT7455, the Company's lead program. CFT7455 is an orally bioavailable MonoDAC targeting IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin's lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. These results, which support clinical evaluation of CFT7455 in non-Hodgkin's lymphomas, were delivered as a poster presentation at the 16th Annual International Conference on Malignant Lymphoma. C4T conducted in vitro studies which demonstrated that CFT7455 binds to cereblon with high affinity, inducing potent and deep degradation of IKZF1 in pre-clinical NHL models. Notable observations include: Cellular competition studies confirmed the high potency of CFT7455 as a cereblon binder. Treatment of the KiJK cell line of anaplastic large cell lymphoma with CFT7455 for 6 hours led to an 89% reduction in IKZF1 protein levels. CFT7455 demonstrated potent antiproliferative activity across a panel of NHL cell lines with MYC, BCL2, and/or BCL6 translocations or rearrangements. This includes in vitro models of cutaneous T-cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, and high-grade B-cell lymphoma. In xenograft models of NHL, CFT7455 achieved improved in vivo potency and efficacy, including deeper and more durable tumor regressions in models of ALCL, diffuse large B-cell lymphoma and MCL, when compared to approved and investigational IMiD therapies. Notable observations include: CFT7455 treatment led to durable tumor regression associated with deep IKZF1 degradation and IRF4 downregulation in KiJK xenografts, where pomalidomide treatment was ineffective at a clinically relevant dose. In the TMD8 DLBCL xenograft model, which proved insensitive to IMiD treatment, CFT7455 promoted tumor regression. In the REC1 MCL xenograft model, doses of CFT7455 greater than or equal to 10 microgram/kg promoted tumor regression. Pharmacodynamic studies showed that CFT7455 promoted degradation of IKZF1 and downregulation of cyclin D1 and E2F1. CFT7455 achieved dose-dependent efficacy in both ALK- and ALK+ xenograft models, from 3-100 microgram/kg with regressions at doses greater than or equal to 30 microgram/kg. In addition, CFT7455 was shown to be between greater than30-100 times more potent than other IKZF1/3 degraders in development. Global proteomic studies showed only IKZF1/3 proteins were significantly degraded in DL-40 tumors with treatment of CFT7455, resulting in modulation of IFN-regulated genes. These results support continued development of CFT7455, which C4T is currently exploring for the treatment of relapsed or refractory multiple myeloma and non-Hodgkin's lymphomas following the initiation of a Phase 1/2 clinical study in June 2021.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$38.00 /

+0.8 (+2.15%)

CCCC C4 Therapeutics
$38.00 /

+0.8 (+2.15%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 17
    Jun
  • 02
    Oct
CCCC C4 Therapeutics
$38.00 /

+0.8 (+2.15%)

CCCC C4 Therapeutics
$38.00 /

+0.8 (+2.15%)

Syndicate
C4 Therapeutics 4.25M share Secondary priced at $37.00 » 20:00
06/16/21
06/16
20:00
06/16/21
20:00
CCCC

C4 Therapeutics

$38.07 /

+0.21 (+0.55%)

The deal priced below…

The deal priced below last closing price of $38.12. JPMorgan, Jefferies, Evercore ISI, BMO Capital and UBS are acting as joint book running managers for the offering.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$38.07 /

+0.21 (+0.55%)

CCCC C4 Therapeutics
$38.07 /

+0.21 (+0.55%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 17
    Jun
  • 02
    Oct
CCCC C4 Therapeutics
$38.07 /

+0.21 (+0.55%)

CCCC C4 Therapeutics
$38.07 /

+0.21 (+0.55%)

On The Fly
Fly Intel: After-Hours Movers » 18:41
06/14/21
06/14
18:41
06/14/21
18:41
BBCP

Concrete Pumping

$8.54 /

+0.14 (+1.67%)

, PDSB

PDS Biotechnology

$12.87 /

+0.8 (+6.63%)

, VRM

Vroom

$45.13 /

+0.92 (+2.08%)

, CCCC

C4 Therapeutics

$42.14 /

-0.05 (-0.12%)

, CBRL

Cracker Barrel

$153.36 /

-1.92 (-1.24%)

, ABR

Arbor Realty

$19.42 /

+0.33 (+1.73%)

, FUSN

Fusion Pharmaceuticals

$8.16 /

+0.01 (+0.12%)

ShowHide Related Items >><<
VRM Vroom
$45.13 /

+0.92 (+2.08%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

CCCC C4 Therapeutics
$42.14 /

-0.05 (-0.12%)

CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

04/22/21 Baird
Concrete Pumping price target raised to $9 from $8 at Baird
01/13/21 B. Riley
Concrete Pumping price target lowered to $6 from $6.75 at B. Riley Securities
01/07/21 B. Riley
Concrete Pumping price target raised to $6.75 from $6.50 at B. Riley Securities
01/05/21 Baird
Concrete Pumping upgraded to Outperform from Neutral at Baird
PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

06/09/21 Oppenheimer
PDS Biotechnology price target raised to $25 from $12 at Oppenheimer
06/09/21 Alliance Global Partners
PDS Biotechnology price target raised to $18 from $6.50 at Alliance Global Partners
06/08/21 Chardan
PDS Biotechnology price target raised to $15 from $11 at Chardan
06/02/21 H.C. Wainwright
PDS Biotechnology price target raised to $20 from $8 at H.C. Wainwright
VRM Vroom
$45.13 /

+0.92 (+2.08%)

05/13/21 Raymond James
Vroom price target raised to $53 from $47 at Raymond James
05/13/21 JMP Securities
Vroom price target raised to $55 from $48 at JMP Securities
05/13/21 Piper Sandler
Vroom price target lowered to $58 from $60 at Piper Sandler
04/13/21 Wedbush
Vroom added to Best List Ideas at Wedbush
CCCC C4 Therapeutics
$42.14 /

-0.05 (-0.12%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

05/26/21 Truist
Cracker Barrel price target raised to $171 from $160 at Truist
04/15/21 CL King
Cracker Barrel downgraded to Neutral from Buy at CL King
04/01/21 MKM Partners
Cracker Barrel price target raised to $160 from $155 at MKM Partners
03/29/21 Deutsche Bank
Deutsche Bank starts Cracker Barrel at Buy, sees 13% share upside
ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

04/26/21 JPMorgan
Arbor Realty price target raised to $18 from $16.50 at JPMorgan
11/06/20 Wolfe Research
Arbor Realty initiated with an Outperform at Wolfe Research
07/28/20 JPMorgan
Arbor Realty upgraded to Overweight on favorable risk/reward at JPMorgan
07/28/20 JPMorgan
Arbor Realty upgraded to Overweight from Neutral at JPMorgan
FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Morgan Stanley
Fusion Pharmaceuticals initiated with an Overweight at Morgan Stanley
07/21/20 Wedbush
Wedbush bullish on Fusion Pharmaceuticals, initiates with an Outperform
07/21/20 Jefferies
Fusion Pharmaceuticals initiated with a Buy at Jefferies
VRM Vroom
$45.13 /

+0.92 (+2.08%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

  • 15
    Jun
  • 15
    Jun
  • 17
    Jun
  • 26
    Mar
  • 07
    Dec
  • 11
    Nov
  • 02
    Oct
  • 11
    Sep
  • 11
    Aug
  • 26
    Jun
VRM Vroom
$45.13 /

+0.92 (+2.08%)

VRM Vroom
$45.13 /

+0.92 (+2.08%)

CBRL Cracker Barrel
$153.36 /

-1.92 (-1.24%)

BBCP Concrete Pumping
$8.54 /

+0.14 (+1.67%)

ABR Arbor Realty
$19.42 /

+0.33 (+1.73%)

VRM Vroom
$45.13 /

+0.92 (+2.08%)

PDSB PDS Biotechnology
$12.87 /

+0.8 (+6.63%)

FUSN Fusion Pharmaceuticals
$8.16 /

+0.01 (+0.12%)

CCCC C4 Therapeutics
$42.14 /

-0.05 (-0.12%)

Syndicate
C4 Therapeutics files to sell 4.25M shares of common stock » 16:10
06/14/21
06/14
16:10
06/14/21
16:10
CCCC

C4 Therapeutics

$41.94 /

-0.25 (-0.59%)

J.P. Morgan, Jefferies, …

J.P. Morgan, Jefferies, Evercore ISI, BMO Capital Markets, and UBS Investment Bank acted as joint book running managers for the offering.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$41.94 /

-0.25 (-0.59%)

CCCC C4 Therapeutics
$41.94 /

-0.25 (-0.59%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 02
    Oct
CCCC C4 Therapeutics
$41.94 /

-0.25 (-0.59%)

Hot Stocks
C4 Therapeutics first patient dosed in phase 1/2 clinical trial on CFT7455 » 08:14
06/14/21
06/14
08:14
06/14/21
08:14
CCCC

C4 Therapeutics

$42.15 /

+0.15 (+0.36%)

C4 Therapeutics announced…

C4 Therapeutics announced that the first patient has been dosed in the company's clinical trial of CFT7455, an orally bioavailable MonoDAC targeting IKZF1/3 for the treatment of multiple myeloma and non-Hodgkin's lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. "Initiating enrollment in the CFT4755 Phase 1/2 trial is a significant milestone in the clinical development of this innovative treatment for hematologic malignancies and reflects C4T's focus on advancing programs in our portfolio that have the potential to improve outcomes for patients with cancer," said Andrew Hirsch, CEO of C4 Therapeutics. "We are excited to learn more about the safety and efficacy of CFT7455 in the current clinical trial and expect to share data from this study in 2022." The Phase 1/2 trial will primarily investigate safety, tolerability, and anti-tumor activity, with secondary and exploratory objectives to characterize the pharmacokinetic and pharmacodynamic profile of CFT7455. The Phase 1 portion of this study will explore CFT7455 as a single agent in patients with relapsed or refractory multiple myeloma and non-Hodgkin's lymphomas, and in combination with dexamethasone in R/R MM patients. Following identification of recommended dosage, the Phase 2 portion of the trial is expected to expand to four investigational arms: relapsed/refractory MM, single agent CFT7455; relapsed/refractory MM, CFT7455 combined with dexamethasone; peripheral T-cell lymphoma, single agent CFT7455; and mantle cell lymphoma, single agent CFT7455. Across the Phase 1/2 trial, C4T plans to enroll a total of approximately 160 patients.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$42.15 /

+0.15 (+0.36%)

CCCC C4 Therapeutics
$42.15 /

+0.15 (+0.36%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 02
    Oct
CCCC C4 Therapeutics
$42.15 /

+0.15 (+0.36%)

Conference/Events
C4 Therapeutics to host conference call » 07:55
06/07/21
06/07
07:55
06/07/21
07:55
CCCC

C4 Therapeutics

$38.97 /

+0.84 (+2.20%)

Management holds a…

Management holds a CFT8919 Pre-Clinical Data Investor conference call on June 7 at 8 am. Webcast Link

ShowHide Related Items >><<
CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 02
    Oct
CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

Hot Stocks
C4 Therapeutics presents preclinical data on CFT8919 » 07:18
06/07/21
06/07
07:18
06/07/21
07:18
CCCC

C4 Therapeutics

$38.97 /

+0.84 (+2.20%)

C4 Therapeutics presented…

C4 Therapeutics presented new pre-clinical data on CFT8919, a novel mutant-selective degrader of epidermal growth factor receptor in non-small cell lung cancer at the Keystone Symposium on Targeted Protein Degradation. The poster presentation shares pre-clinical data that suggests CFT8919 may be active as a single agent in patients with resistance to EGFR inhibitors due to secondary mutations in EGFR, including T790M and C797S, as well as in the front-line setting with the potential to avoid the emergence of resistance-causing secondary EGFR mutations seen with currently approved EGFR inhibitors. C4T conducted in vitro and in vivo studies that show CFT8919 is a potent and highly selective orally bioavailable degrader of EGFR L858R with broad coverage of on-target resistance mutations as well as intracranial activity. Notable observations include: In cancer cell lines, CFT8919 induces degradation of EGFR L858R at low nanomolar concentrations while no degradation of wild type is induced up to 10 microM. CFT8919 demonstrates equipotent activity against EGFR mutations resistant to EGFR inhibition, including L858R-C797S, L858R-T790M, and L858R-T790M-C797S compared to L858R single mutation in Ba/F3 cell models in vitro. Kinome profiling and global proteomic evaluation did not identify any significant off-target activity of CFT8919. CFT8919 does not induce degradation of known cereblon neo-substrates SALL4 or GSPT1, indicating that the potential associated toxicities will not be liabilities. Additionally, in vivo data demonstrates the following: CFT8919 degrades and inhibits mutant EGFR in tumors upon oral administration. In the NCI-H1975 EGFR-L858R-T790M xenograft model, after a single oral dose of CFT8919, up to 85 percent of mutant EGFR was degraded in tumors accompanied with near-complete inhibition of phospho-EGFR. In this model, twice-daily oral administration of CFT8919 showed dose-dependent anti-tumor activity and regressions comparable to osimertinib. In BaF3 allograft model expressing EGFR-L858R-T790M-C797S, CFT8919 demonstrates anti-tumor activity resulting in tumor regression, while osimertinib is inactive. CFT8919 demonstrates rapid and significant reductions in tumor burden in the H1975-LUC brain metastasis model after oral dosing, indicating its potential to be active in the central nervous system. This promising pre-clinical data supports the Company's decision to advance CFT8919 into investigational new drug-enabling studies this year. C4T anticipates filing an IND for CFT8919 by mid-2022, with the goal to initiate a Phase 1 clinical trial by year-end 2022.

ShowHide Related Items >><<
CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 02
    Oct
CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

Conference/Events
C4 Therapeutics to host conference call » 04:55
06/07/21
06/07
04:55
06/07/21
04:55
CCCC

C4 Therapeutics

$38.97 /

+0.84 (+2.20%)

Management holds a…

Management holds a CFT8919 Pre-Clinical Data Investor conference call on June 7 at 8 am. Webcast Link

ShowHide Related Items >><<
CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

06/04/21 H.C. Wainwright
C4 Therapeutics initiated with a Buy at H.C. Wainwright
03/31/21 BMO Capital
C4 Therapeutics initiated with an Outperform at BMO Capital
12/08/20 BMO Capital
C4 Therapeutics price target raised to $45 from $33 at BMO Capital
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
  • 02
    Oct
CCCC C4 Therapeutics
$38.97 /

+0.84 (+2.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.